A recent study confirmed a consensus rating of the Outcome Measures in Rheumatology Trials (OMERACT) total joint replacement (TJR) core domain set as critical for patients. This broad endorsement should encourage the identification of candidate outcome instruments to further develop a TJR core measurement set that can harmonize reporting in TJR clinical trials. Researchers emailed a survey to 3,810 hip/knee arthroplasty patients and 49 arthroplasty surgeons at a high-volume arthroplasty center to rate the importance of each core domain (ie, pain, function, patient satisfaction, revision surgery, adverse events, and death) and 2 additional domains (ie, cost and participation). They found:

• The questionnaire was completed by 1,295 patients (34%) and 21 surgeons (43%).
• Patient non-responders were similar to responders in age (≥55 years, 85.7% vs 88.6%), sex (female, 57.5% vs 57.3%), and joint procedure (total hip replacement, 56.9% vs 63.2%).
• Overall, all core domains and 1 non-core domain (ie, participation) were confirmed as “critical” by both stakeholder groups.